Vincristine, also known as leurocristine and sold under the brand name Oncovin among others, is a chemotherapy medication used to treat a number of types of cancer. This includes acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin lymphoma, non Hodgkin lymphoma, neuroblastoma and certain solid tumors when used in combination regimens. Vincristine sulfate is the clinically used salt; it is a vinca alkaloid that binds to tubulin, prevents microtubule polymerization, arrests cells in metaphase and interferes with axonal transport, producing dose limiting neurotoxicity such as peripheral neuropathy and autonomic dysfunction. The drug is administered intravenously by trained clinicians, typically dosed by body surface area and often incorporated into multi agent protocols; analytical characterization of the active pharmaceutical ingredient includes HPLC, LC MS and NMR to confirm identity, purity and potency.
Parent: Vincristine
Parent: Vincristine
Parent: Vincristine
Parent: Vincristine / Vinblastine
Parent: Vincristine
Parent: Vincristine
Parent: Vincristine
Parent: Vincristine
Parent: Vincristine / Vindesine
Parent: Vincristine/ Vincristine Sulfate
The impurity profile for vincristine API and finished product commonly includes structurally related vinca alkaloids and degradation products such as vinblastine, vindesine, desacetylvincristine, N oxide derivatives and small polar or deacetylated fragments formed during synthesis or storage. Typical analytical acceptance ranges used in industry and in many quality control specifications are on the order of single digit tenths of a percent for individual related substances, for example individual related compounds often specified at not more than about 0.2 to 0.5 percent relative to the API peak, with a total related substances limit commonly set at or below approximately 1.0 percent, although exact limits are product specific and set by pharmacopeial monographs and regulatory dossiers. Routine control relies on validated stability indicating HPLC or LC MS methods, forced degradation studies to identify degradants, and qualification of impurities present above established thresholds.
Vincristine is used to treat multiple cancers including acute lymphocytic leukemia, some cases of acute myeloid leukemia, Hodgkin and non Hodgkin lymphomas, neuroblastoma and various combination chemotherapy regimens for solid tumors; it is rarely used as a single agent for adult solid tumors and is given intravenously under medical supervision.
Vincristine binds to tubulin and inhibits microtubule polymerization, preventing formation of the mitotic spindle, causing mitotic arrest in metaphase; it also disrupts axonal microtubules, which underlies its neurotoxic effects and interference with intracellular transport.
Yes, vincristine is considered a high risk cytotoxic agent because of its narrow therapeutic index, potential for severe dose dependent neurotoxicity and systemic toxicities, and the need for specialist handling, dosing and monitoring by oncology professionals; errors in administration, such as intrathecal injection, are catastrophic and universally contraindicated.
Vincristine can induce tumor cell death and tumor shrinkage as part of effective chemotherapy regimens, particularly in hematologic malignancies and some pediatric solid tumors, but response depends on tumor type, stage, combination therapy and individual patient factors; it is usually one component of multi agent treatment rather than a sole curative agent.
